<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431780</url>
  </required_header>
  <id_info>
    <org_study_id>GB01/14UCC</org_study_id>
    <nct_id>NCT02431780</nct_id>
  </id_info>
  <brief_title>A Multicentre Clinical Investigation of a Decision Support Algorithm for Neonatal Seizure Detection</brief_title>
  <acronym>ANSeR</acronym>
  <official_title>A Multi-centre, Randomised, Controlled, Clinical Investigation of a Standalone Decision Support Algorithm for Neonatal Seizure Recognition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Cork</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Cork</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ANSeR Clinical Investigation is a multi-centre, randomised, controlled, clinical&#xD;
      investigation of a standalone decision support Algorithm for Neonatal Seizure Recognition,&#xD;
      the ANSER Software system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open, two arm, parallel group, randomised, controlled investigation of the&#xD;
      ANSeR Software System as a stand-alone neonatal seizure recognition decision support tool.&#xD;
      Term neonates requiring EEG monitoring will be stratified by recruiting site and then&#xD;
      randomised to receive either EEG monitoring with the ANSeR Software System or EEG monitoring&#xD;
      without the ANSeR Software System.&#xD;
&#xD;
      It is proposed that the rate of true detections (sensitivity) of investigation personnel&#xD;
      using the ANSeR Software System in clinical practice will be at least 25% higher than that of&#xD;
      investigation personnel not using the ANSeR Software System in routine clinical practice. In&#xD;
      addition we expect the specificity of investigation personnel using the ANSeR Software System&#xD;
      to be no worse than 10% less than that of investigation personnel not using the ANSeR&#xD;
      Software System. This should result in more appropriate and timely use of antiepileptic drugs&#xD;
      (AED).&#xD;
&#xD;
      Randomisation Immediately following enrolment in the investigation, each participant will be&#xD;
      randomly assigned to receive either EEG monitoring with the ANSeR Software System or without&#xD;
      the ANSeR Software System. Randomisation will be stratified by recruiting site with a 1:1&#xD;
      allocation ratio to each group. Block randomisation with varying block sizes will be used and&#xD;
      the randomisation and allocation will be performed centrally using a web-based electronic&#xD;
      system.&#xD;
&#xD;
      Blinding As this is an investigation of a medical device (software), the investigation&#xD;
      personnel will be aware of which group the participant is assigned to. The expert panel who&#xD;
      are the diagnostic reference standard will be blinded to group allocation. The&#xD;
      biostatistician will also be blinded to group allocation during the analysis of the data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Seizure Detection Rate for all Neonates enrolled in the investigation arm compared to Seizure Detection Rate for all Neonates in the control arm.</measure>
    <time_frame>12-18 months</time_frame>
    <description>The rate of true seizure detection (sensitivity), as recorded on a Seizure Record form, 25% superior in the investigation arm compared to the control group (usual clinical practice). The Expert Committee will be used as the diagnostic reference standard.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The False Detections per hour (sensitivity) for all Neonates enrolled in the investigation arm compared to the False Detection Rate for all Neonates in the control arm.</measure>
    <time_frame>12-18 months</time_frame>
    <description>The False Detections per hour (specificity), as recorded on a Seizure Record form, 10% superior in the investigation arm compared to the control group (usual clinical practice). The Expert Committee will be used as the diagnostic reference standard.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seizure burden (min) for all Neonates enrolled in the investigation arm compared to Seizure burden (min) for all Neonates in the control arm.</measure>
    <time_frame>12-18 months</time_frame>
    <description>To quantify seizure burden (min) in the investigation arm and control arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Neonates administered Anti-epileptic drug (AED) in the investigation arm compared to Number of Neonates administered Anti-epileptic drug (AED) in the control arm.</measure>
    <time_frame>12-18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">264</enrollment>
  <condition>Seizures</condition>
  <condition>Brain Diseases</condition>
  <condition>Central Nervous System Diseases</condition>
  <condition>Epilepsy</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Neurologic Manifestations</condition>
  <arm_group>
    <arm_group_label>non ANSeR Software System</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Routine clinical EEG monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANSeR Software System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intended use of the ANSeR Software System is to provide a real time decision support tool to assist in the diagnosis of seizures in neonates (between 36 weeks and 44 weeks corrected age) and to provide a review tool for EEG and seizure analysis. ANSeR is intended to provide a reliable, effective, objective and intuitive means of identifying seizures</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ANSeR Software System</intervention_name>
    <description>ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool</description>
    <arm_group_label>ANSeR Software System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neonates 36 weeks - 44 weeks corrected gestational age in whom EEG monitoring is&#xD;
             indicated because they are deemed to be&#xD;
&#xD;
               -  at high risk of seizures or&#xD;
&#xD;
               -  are experiencing seizures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  â€¢ No parental/guardian consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>36 Weeks</minimum_age>
    <maximum_age>44 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Rennie, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College London Hospitals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geraldine Boylan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College Cork, Cork, Ireland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cork University Maternity Hospital</name>
      <address>
        <city>Wilton</city>
        <state>Cork</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotunda Maternity Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Centre Utrecht, Wilhelmina Children's Hospital</name>
      <address>
        <city>Utrecht</city>
        <zip>KE 04.123.1, Po Box 85090</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska Institutet and University Hospital</name>
      <address>
        <city>Huddinge</city>
        <state>Stockholm</state>
        <zip>K78 141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts and the London NHS Trust,</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The London and Homerton Hospital</name>
      <address>
        <city>London</city>
        <zip>E9 6SR.</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital</name>
      <address>
        <city>London</city>
        <zip>WC1N3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://anserstudy.com/</url>
    <description>ANSeR Study Research Group</description>
  </link>
  <results_reference>
    <citation>Pavel AM, Rennie JM, de Vries LS, Blennow M, Foran A, Shah DK, Pressler RM, Kapellou O, Dempsey EM, Mathieson SR, Pavlidis E, van Huffelen AC, Livingstone V, Toet MC, Weeke LC, Finder M, Mitra S, Murray DM, Marnane WP, Boylan GB. A machine-learning algorithm for neonatal seizure recognition: a multicentre, randomised, controlled trial. Lancet Child Adolesc Health. 2020 Oct;4(10):740-749. doi: 10.1016/S2352-4642(20)30239-X. Epub 2020 Aug 27.</citation>
    <PMID>32861271</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2015</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College Cork</investigator_affiliation>
    <investigator_full_name>Professor Geraldine Boylan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Neonatal Seizures</keyword>
  <keyword>Decision Support Algorithm</keyword>
  <keyword>EEG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Central Nervous System Diseases</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

